Aigen Investment Management, LP Bei Gene, Ltd. Transaction History

Aigen Investment Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $259,425 - $329,583	1,635 New	1,635 $294,000
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $503,262 - $640,957	2,335 New	2,335 $503,000
Q1 2022 May 05, 2022	SELL	$146.52 - $269.56 $103,003 - $189,500	-703 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $174,737 - $273,706	703 New	703 $201,000
Q1 2021 May 11, 2021	SELL	$260.64 - $382.12 $1.48 Million - $2.17 Million	-5,684 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $1.26 Million - $1.8 Million	5,684 New	5,684 $1.47 Million

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.